Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicine, western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau, and internationally. More Details
Fair value with imperfect balance sheet.
Share Price & News
How has Wai Yuen Tong Medicine Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 897 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 897's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 897 exceeded the Hong Kong Pharmaceuticals industry which returned 20.9% over the past year.
Return vs Market: 897 underperformed the Hong Kong Market which returned 29.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Wai Yuen Tong Medicine Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StHealth Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
2 months ago | Simply Wall StWai Yuen Tong Medicine Holdings' (HKG:897) Shareholders Are Down 75% On Their Shares
3 months ago | Simply Wall StHealth Check: How Prudently Does Wai Yuen Tong Medicine Holdings (HKG:897) Use Debt?
Is Wai Yuen Tong Medicine Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 897 (HK$0.33) is trading below our estimate of fair value (HK$7.8)
Significantly Below Fair Value: 897 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 897 is unprofitable, so we can't compare its PE Ratio to the HK Pharmaceuticals industry average.
PE vs Market: 897 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 897's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 897 is good value based on its PB Ratio (0.2x) compared to the HK Pharmaceuticals industry average (1.3x).
How is Wai Yuen Tong Medicine Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wai Yuen Tong Medicine Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Wai Yuen Tong Medicine Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 897 is currently unprofitable.
Growing Profit Margin: 897 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 897 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.9% per year.
Accelerating Growth: Unable to compare 897's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 897 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 897 has a negative Return on Equity (-5.61%), as it is currently unprofitable.
How is Wai Yuen Tong Medicine Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 897's short term assets (HK$3.3B) exceed its short term liabilities (HK$2.8B).
Long Term Liabilities: 897's short term assets (HK$3.3B) exceed its long term liabilities (HK$1.8B).
Debt to Equity History and Analysis
Debt Level: 897's debt to equity ratio (54.5%) is considered high.
Reducing Debt: 897's debt to equity ratio has increased from 25% to 54.5% over the past 5 years.
Debt Coverage: 897's debt is not well covered by operating cash flow (12.8%).
Interest Coverage: Insufficient data to determine if 897's interest payments on its debt are well covered by EBIT.
What is Wai Yuen Tong Medicine Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 897's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 897's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 897's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 897's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 897 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 897's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ching Ho Tang (58 yo)
Mr. Ching Ho Tang, SBS, JP is Chairman of China Agri-Products Exchange Limited since February 8, 2021. Mr. Tang Co-founded Wang On Group Ltd., in 1987 and served as its Managing Director. Mr. Tang was resp...
CEO Compensation Analysis
Compensation vs Market: Ching Ho's total compensation ($USD1.88M) is above average for companies of similar size in the Hong Kong market ($USD230.00K).
Compensation vs Earnings: Ching Ho's compensation has increased whilst the company is unprofitable.
Experienced Management: 897's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Experienced Board: 897's board of directors are seasoned and experienced ( 15 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Wai Yuen Tong Medicine Holdings Limited's company bio, employee growth, exchange listings and data sources
- Name: Wai Yuen Tong Medicine Holdings Limited
- Ticker: 897
- Exchange: SEHK
- Founded: 1897
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$406.442m
- Shares outstanding: 1.23b
- Website: https://www.wyth.net
Number of Employees
- Wai Yuen Tong Medicine Holdings Limited
- Skyline Tower
- 31st Floor
- Kowloon Bay
- Hong Kong
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicine, western pharmaceutical products, and health food and personal prod...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 10:14|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.